MREO

Mereo BioPharma Group PLC ADR

MREO, USA

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

https://www.mereobiopharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MREO
stock
MREO

Patterns Watch: How strong is Climb Bio Inc stock balance sheet - Weekly Trade Recap & Capital Protection Trading Alerts moha.gov.vn

Read more →
MREO
stock
MREO

Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO) Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7.1256

Analyst Picks

Strong Buy

6

Buy

2

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

7.64

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-15.07 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.10 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.15

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 59.46% of the total shares of Mereo BioPharma Group PLC ADR

1.

HHG PLC

(11.1181%)

since

2025/06/30

2.

Rubric Capital Management LP

(9.6214%)

since

2025/06/30

3.

Mangrove Partners

(5.4284%)

since

2025/06/30

4.

Deerfield Management Co

(4.2178%)

since

2025/06/30

5.

Alkeon Capital Management, LLC

(2.953%)

since

2025/06/30

6.

Rock Springs Capital Management LP

(2.8066%)

since

2025/06/30

7.

683 Capital Management LLC

(2.7342%)

since

2025/06/30

8.

Clearline Capital LP

(2.2742%)

since

2025/06/30

9.

Goldman Sachs Group Inc

(1.9423%)

since

2025/06/30

10.

Aberdeen Group PLC

(1.9038%)

since

2025/06/30

11.

abrdn World Healthcare

(1.8247%)

since

2025/07/31

12.

Tejara Capital Ltd

(1.5276%)

since

2025/06/30

13.

abrdn Life Sciences Investors

(1.3051%)

since

2025/08/31

14.

UBS (Lux) EF Biotech (USD) P-acc

(1.0719%)

since

2025/05/31

15.

Renaissance Technologies Corp

(0.9305%)

since

2025/06/30

16.

FMR Inc

(0.9293%)

since

2025/06/30

17.

Fidelity Select Health Care

(0.9249%)

since

2025/07/31

18.

Schonfeld Strategic Advisors LLC

(0.5718%)

since

2025/06/30

19.

Fidelity Select Biotechnology

(0.5355%)

since

2025/07/31

20.

Morgan Stanley - Brokerage Accounts

(0.4936%)

since

2025/06/30

21.

Marshall Wace Asset Management Ltd

(0.4826%)

since

2025/06/30

22.

Atle Fund Management AB

(0.4808%)

since

2025/06/30

23.

Citadel Advisors Llc

(0.4781%)

since

2025/06/30

24.

Fidelity Advisor Biotechnology I

(0.4771%)

since

2025/07/31

25.

Fidelity Advisor Health Care I

(0.4717%)

since

2025/07/31

26.

Two Sigma Investments LLC

(0.4143%)

since

2025/06/30

27.

Soleus Capital Management, L.P.

(0.3769%)

since

2025/06/30

28.

HealthInvest Sustainable Healthcare E

(0.3376%)

since

2025/07/31

29.

iShares Genomics Immnlgy & Hlthcr ETF

(0.2252%)

since

2025/08/31

30.

Healthlnvest S&M Cap Healthcare C

(0.1432%)

since

2025/07/31

31.

Fidelity VIP Health Care Initial

(0.1287%)

since

2025/07/31

32.

UBS Global Equity Biotech

(0.0805%)

since

2025/06/30

34.

Fidelity Nasdaq Composite Index

(0.0582%)

since

2025/07/31

35.

Arctic Aurora LifeScience I

(0.0349%)

since

2025/07/31

36.

Virtus LifeSci Biotech Clinical Trls ETF

(0.0277%)

since

2025/08/29

37.

Avanza Healthcare by Samuelsson & Hult

(0.024%)

since

2025/08/31

38.

ActivePassive International Equity ETF

(0.0174%)

since

2025/08/29

39.

Forefront Tiresias Strategy

(0.012%)

since

2025/06/30

40.

iShares Genomics Imnlgy & Hlthcr ETF CAD

(0.0069%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

0.0014

Latest Release

Date

2025-09-30

EPS Actual

-0.01

EPS Estimate

0.0133

EPS Difference

-0.0233

Surprise Percent

-175.188%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.